Science News

In the January 2015 issue of Lancet Neurology, Randall Bateman, MD, reviews top achievements in Alzheimer’s research in 2014. A long-time colleague of BrightFocus and one of our current grantees, Bateman is the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University of St. Louis Medical School.

A new study suggests that many people with AMD may not be getting their treatment benefits—or their money’s worth—from their ocular vitamins. It turns out that many of the products being marketed may not contain identical ingredient dosages to the AREDS and AREDS2 formulas.

More than 250 science journalists covered the Society for Neuroscience meeting in Washington, DC, this week. Two close colleagues of BrightFocus took part in press conferences to explain new directions in Alzheimer’s research.

A leading government science officer addressed BrightFocus grantees attending our annual breakfast sponsored during the Society for Neuroscience (SfN) meeting, which was held in Washington, DC, this week.

For the Alzheimer’s community, new drugs cannot come fast enough. In recent years, trials of disease-modifying drugs have been disappointing, yet they’ve brought valuable knowledge about the optimal timing for when Alzheimer’s can be stopped. Today, there’s a sense that a breakthrough is near. There’s a quantum leap of activity aimed at slowing down Alzheimer’s decades before symptoms appear.